Lanreotide Sun

Lanreotide, the active ingredient in Lanreotide Sun, is a somatostatin analog presented as a subcutaneous formulation for injection use. It is employed to control hormone excess in conditions such as acromegaly, neuroendocrine tumors and Cushing's disease, primarily in adult patients.

GNH USA supplies Lanreotide Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across EU and other markets. The company ensures temperature‑controlled logistics and comprehensive documentation for seamless importation.

Lanreotide is a somatostatin analog used to manage hormone‑driven disorders. - Acromegaly: Reduces excess growth hormone secretion, helping to normalize IGF‑1 levels and control disease activity. - Neuroendocrine tumors (carcinoid): Inhibits secretion of vasoactive peptides, improving symptom control and tumor progression. - Cushing's disease: Suppresses ACTH production, aiding in the reduction of cortisol excess.

Lanreotide may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site pain: Discomfort or erythema at the subcutaneous injection site. - Gastrointestinal disturbances: Nausea, abdominal pain, or diarrhea. - Hyperglycaemia: Elevated blood glucose levels, especially in diabetic patients. - Headache: Mild to moderate headache episodes.

Serious or Rare Side Effects: - Gallbladder disease: Biliary sludge or cholelithiasis leading to gallstone formation. - Pancreatitis: Inflammation of the pancreas presenting with severe abdominal pain. - Allergic reactions: Anaphylaxis or severe hypersensitivity requiring immediate medical attention.

When prescribing Lanreotide, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: Evaluate patients for pre‑existing heart disease before initiation. - Glucose monitoring: Check blood glucose regularly, particularly in those with diabetes or impaired tolerance. - Gallbladder evaluation: Perform baseline imaging if history of gallstones or biliary disease exists. - Thyroid function: Monitor thyroid hormones as somatostatin analogues can affect thyroid activity. - Pregnancy and lactation: Use only if potential benefit justifies potential risk; data are limited. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Cytochrome P450 inducers: Strong inducers such as rifampicin may reduce lanreotide exposure. - Somatostatin analog antagonists: Concurrent use may blunt therapeutic effect.

Moderate Interactions (Monitor Closely): - Oral hypoglycaemic agents: May require dose adjustment due to altered glucose metabolism. - Anticoagulants: Potential for increased bleeding risk; monitor coagulation parameters. - Thyroid hormone replacement: May need titration as lanreotide can affect hormone levels.